This protein mediates the secretion of IL-1β, requiring K+ outflow and mitochondrial ROS production [40,41], elucidating the potential of the NLRP3 inflammasome as a molecular target for COVID-19 treatment. This evidence concerns the gene NLRP3 and COVID-19.